GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BOLT · Mar 31, 2025

Bolt Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000950170-25-069188General Corporate
Operating cash generation45thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1093.70% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-76.83% · CORE · NOT_ENOUGH_HISTORY

Operating margin64thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.operating_margin

-991.41% · CORE · VALID

R&D intensity27thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

778.40% · OPTIONAL · VALID

SBC intensity9thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

58.02% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-797.00%
Current
-1093.70%
Delta
-296.70%
Growth Decreased
Previous
-2.36%
Current
-76.83%
Delta
-74.47%
Profitability Decreased
Previous
-949.91%
Current
-991.41%
Delta
-41.50%
R And D Intensity Increased
Previous
747.32%
Current
778.40%
Delta
31.07%
Sbc Intensity Decreased
Previous
96.32%
Current
58.02%
Delta
-38.30%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.